SCI时时刷

search
+
Sequelae of B-Cell Depleting Therapy: An Immunologist’s Perspective
Sequelae of B-Cell Depleting Therapy: An Immunologist’s Perspective
B-cell depleting therapy (BCDT) has revolutionised the treatment of B-cell malignancies and autoimmune diseases by targeti...
The Evolving Applications of Bispecific Antibodies: Reaping the Harvest of Early Sowing and Planting New Seeds
The Evolving Applications of Bispecific Antibodies: Reaping the Harvest of Early Sowing and Planting New Seeds
After decades of gradual progress from conceptualization to early clinical trials (1960–2000), the therapeutic poten...
Investigational RNA Interference Agents for Hepatitis B
Investigational RNA Interference Agents for Hepatitis B
Functional cure of chronic hepatitis B (CHB)—defined as sustained seroclearance of hepatitis B surface antigen (HBsA...
Relevance of Neutralizing Antibodies for the Pharmacokinetics of Pegunigalsidase Alfa in Patients with Fabry Disease
Relevance of Neutralizing Antibodies for the Pharmacokinetics of Pegunigalsidase Alfa in Patients with Fabry Disease
Pegunigalsidase alfa is a newly approved drug for the treatment of Fabry disease, designed to increase the plasma half-lif...
Accelerating CAR-T Cell Therapies with Small-Molecule Inhibitors
Accelerating CAR-T Cell Therapies with Small-Molecule Inhibitors
Chimeric antigen receptor T-cell therapies have markedly improved the survival rates of patients with B-cell malignancies....
Effect of Biological Therapy for Psoriasis on the Development of Psoriatic Arthritis: A Population-Based Cohort Study
Effect of Biological Therapy for Psoriasis on the Development of Psoriatic Arthritis: A Population-Based Cohort Study
Evidence comparing the impact of various biologics for psoriasis on the progression to psoriatic arthritis (PsA) is limite...
Discovery of Therapeutic Antibodies Targeting Complex Multi-Spanning Membrane Proteins
Discovery of Therapeutic Antibodies Targeting Complex Multi-Spanning Membrane Proteins
Complex integral membrane proteins, which are embedded in the cell surface lipid bilayer by multiple transmembrane spannin...
Eblasakimab, an Anti-IL‑13Rα1 Antibody, Reduces Atopy-Associated Serum Biomarkers in Moderate‑to‑Severe Atopic Dermatitis
Eblasakimab, an Anti-IL‑13Rα1 Antibody, Reduces Atopy-Associated Serum Biomarkers in Moderate‑to‑Severe Atopic Dermatitis
Eblasakimab, a first-in-class monoclonal antibody with a unique mechanism to target the interleukin (IL)-13 receptor alpha...
Advanced Therapy Medicinal Products: Availability, Access and Expenditure in Italy
Advanced Therapy Medicinal Products: Availability, Access and Expenditure in Italy
Advanced therapy medicinal products (ATMPs) are an innovative output of biomedical research, characterized by a high level...
Real-World Comparative Analysis of Trastuzumab Originator and Biosimilars: Safety, Efficacy, and Cost Effectiveness
Real-World Comparative Analysis of Trastuzumab Originator and Biosimilars: Safety, Efficacy, and Cost Effectiveness
Despite the global use of trastuzumab biosimilars, concerns remain regarding their efficacy and safety. In particular, whe...
Adverse Impacts of PEGylated Protein Therapeutics: A Targeted Literature Review
Adverse Impacts of PEGylated Protein Therapeutics: A Targeted Literature Review
The beneficial effects of polyethylene glycol (PEG)-conjugated therapeutics, such as increased half-life, solubility, stab...
Patient Satisfaction and Experience with CT-P17 Following Transition from Reference Adalimumab or Another Adalimumab Biosimilar: Results from the Real-World YU-MATTER Study
Patient Satisfaction and Experience with CT-P17 Following Transition from Reference Adalimumab or Another Adalimumab Biosimilar: Results from the Real-World YU-MATTER Study
Biosimilars are cost-effective alternatives to reference products for patients with inflammatory bowel diseases (IBD) and ...
Biochemical Amenability in Fabry Patients Under Chaperone Therapy—How and When to Test?
Biochemical Amenability in Fabry Patients Under Chaperone Therapy—How and When to Test?
Current recommendations for Fabry disease include α-galactosidase A (AGAL) activity measurements to assess the bioche...
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab
A biosimilar medicine is a successor to a reference (‘originator’/’original-brand’) biologic medic...
Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects
Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects
Nivolumab (Opdivo®) is the first anti-PD-1 antibody approved in the world. LY01015 is a potential biosimilar of nivol...
Chikungunya Virus Vaccines: A Review of IXCHIQ and PXVX0317 from Pre-Clinical Evaluation to Licensure
Chikungunya Virus Vaccines: A Review of IXCHIQ and PXVX0317 from Pre-Clinical Evaluation to Licensure
Chikungunya virus is an emerging mosquito-borne alphavirus that causes febrile illness and arthritic disease. Chikungunya ...
Pulmonary Arterial Hypertension and TGF-β Superfamily Signaling: Focus on Sotatercept
Pulmonary Arterial Hypertension and TGF-β Superfamily Signaling: Focus on Sotatercept
Pulmonary arterial hypertension (PAH) is a rare and progressive disease that continues to remain highly morbid despite mul...
Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study
Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study
The optimal infliximab dose intensification strategy to address loss of response associated with subtherapeutic i...
Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond
Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond
Mucopolysaccharidosis type II (MPS II) is a rare, pediatric, neurometabolic disorder due to the lack of activity of the ly...
Systematic Review of Genetic Substrate Reduction Therapy in Lysosomal Storage Diseases: Opportunities, Challenges and Delivery Systems
Systematic Review of Genetic Substrate Reduction Therapy in Lysosomal Storage Diseases: Opportunities, Challenges and Delivery Systems
Genetic substrate reduction therapy (gSRT), which involves the use of nucleic acids to downregulate the genes involved in ...
A Population Pharmacokinetic Model of Tocilizumab in Kidney Transplant Patients Treated for Chronic Active Antibody-Mediated Rejection: Comparison of Plasma Exposure Between Intravenous and Subcutaneous Administration Schemes
A Population Pharmacokinetic Model of Tocilizumab in Kidney Transplant Patients Treated for Chronic Active Antibody-Mediated Rejection: Comparison of Plasma Exposure Between Intravenous and Subcutaneous Administration Schemes
Tocilizumab prevents the clinical worsening of chronic active antibody-mediated rejection (CAAMR) in kidney transplant rec...
Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors
Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors
Chimeric antigen receptor T cell therapy has been established in the treatment of various B cell maligna...
Long-Term Efficacy and Safety of Stapokibart in Adults with Moderate-to-Severe Atopic Dermatitis: An Open-Label Extension, Nonrandomized Clinical Trial
Long-Term Efficacy and Safety of Stapokibart in Adults with Moderate-to-Severe Atopic Dermatitis: An Open-Label Extension, Nonrandomized Clinical Trial
Stapokibart/CM310, a humanized monoclonal antibody targeting the interleukin-4 receptor α chain, has shown promising ...
Insulin Icodec: First Approval
Insulin Icodec: First Approval
Insulin icodec (AWIQLI®) is an ultra-long-acting basal insulin analogue that is being developed by Novo Nordisk for t...
Monoclonal Antibody Generation Using Single B Cell Screening for Treating Infectious Diseases
Monoclonal Antibody Generation Using Single B Cell Screening for Treating Infectious Diseases
The screening of antigen-specific B cells has been pivotal for biotherapeutic development for over four decades. Conventio...
Outcomes of Rituximab-abbs versus Rituximab in Patients with Diffuse Large B-Cell Lymphoma in a Noninferiority Study
Outcomes of Rituximab-abbs versus Rituximab in Patients with Diffuse Large B-Cell Lymphoma in a Noninferiority Study
Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is one of the first line treatments for...
Stem Cells and Stem Cell-Derived Factors for the Treatment of Inflammatory Bowel Disease with a Particular Focus on Perianal Fistulizing Disease: A Minireview on Future Perspectives
Stem Cells and Stem Cell-Derived Factors for the Treatment of Inflammatory Bowel Disease with a Particular Focus on Perianal Fistulizing Disease: A Minireview on Future Perspectives
Inflammatory bowel disease remains a difficult disease to effectively treat, especially fistulizing Crohn’s disease....
Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs
Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs
Antisense oligonucleotides (ASOs) are single stranded nucleic acids that target RNA. The US Food and Drug Administration h...
Barriers and Enablers Affecting the Uptake of Biosimilar Medicines Viewed Through the Lens of Actor Network Theory: A Systematic Review
Barriers and Enablers Affecting the Uptake of Biosimilar Medicines Viewed Through the Lens of Actor Network Theory: A Systematic Review
Biosimilars represent an opportunity to realise savings against the costs of innovative medicines. Despite efforts made by...
Demonstration of Physicochemical and Functional Similarity of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab
Demonstration of Physicochemical and Functional Similarity of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab
Tocilizumab is an immunoglobulin G1 monoclonal antibody targeting the interleukin-6 receptor (IL-6R). BAT1806/BIIB800 (toc...
阅读更多
format_indent_increase